Skip to main content
main-content

01.12.2018 | Research | Ausgabe 1/2018 Open Access

Journal of Neuroinflammation 1/2018

Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke

Zeitschrift:
Journal of Neuroinflammation > Ausgabe 1/2018
Autoren:
Miaodan Li, Shumin Chen, Xue Shi, Chenfei Lyu, Yongfang Zhang, Miaoqin Tan, Chen Wang, Nailiang Zang, Xiaoxi Liu, Yafang Hu, Jiangang Shen, Liang Zhou, Yong Gu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12974-018-1267-5) contains supplementary material, which is available to authorized users.

Abstract

Background

Blood–brain barrier (BBB) breakdown and inflammatory responses are the major causes of tissue-type plasminogen activator (tPA)-induced hemorrhagic transformation (HT), while high-mobility group box 1 (HMGB1) exacerbates inflammatory damage to BBB during the process of brain ischemia/reperfusion. This study aimed to investigate the change of HMGB1 after thrombolytic therapy and whether blocking HMGB1 could ameliorate the neurovasculature complications secondary to tPA treatment in stroke rats.

Methods

Sera from acute stroke patients and rats with thrombolytic therapy were collected to investigate HMGB1 secretion. Male Sprague-Dawley rats with 2 h or 4.5 h middle cerebral artery occlusion were continuously infused with tPA followed by administration of membrane permeable HMGB1-binding heptamer peptide (HBHP). The mortality rate, neurological score, HT, brain swelling, BBB permeability, and inflammatory factors were determined.

Results

The results revealed that HMGB1 levels were elevated in both stroke patients and rats after tPA treatment. Blocking HMGB1 signaling by HBHP in the rat model of 4.5 h brain ischemia significantly attenuated tPA-related complications, including mortality rate, the degree of hemorrhage, brain swelling, neurological deficits, BBB impairment, microglia activation, and the expressions of inflammatory cytokines.

Conclusions

tPA treatment might induce HMGB1 secretion while blocking HMGB1 with HBHP could markedly reduce the risk of thrombolysis-associated brain hemorrhage and mortality through attenuating BBB damage and inflammatory reactions. These results indicate that HMGB1 may potentiate the risk of HT in tPA administration and that blocking HMGB1 signaling would be helpful in preventing complications brought by thrombolysis in ischemic stroke.

Trial registration

http://​www.​chictr.​org.​cn. Unique identifier: ChiCTR-OOC-16010052. Registered 30 November 2016.
Zusatzmaterial
Additional file 1: Figure S1. Western blot analysis indicated serum HMGB1 levels were elevated after thrombolysis in stroke patients and rats. Sera from human and rats received thrombolysis were incubated with Protein A/G MagBeads (GenScript, Piscataway, NJ) to remove immunoglobins and then the proteins were separated in SDS-PAGE gels and immunolabeled with HMGB1 antibody. (PDF 340 kb)
12974_2018_1267_MOESM1_ESM.pdf
Additional file 2: Figure S2. HBHP and HMGBP could not directly interact with tPA. Biolayer interferometry binding measurements using BLItz system from ForteBio were used to detect the binding affinity of HBHP and HMGBP with tPA. (A) Proteins were biotinylated and immobilized on streptavidin-coated biosensor tips. After equilibration, the tips were probed with the interacting analytes. The complexes were dissociated by immersing the sensor into sample dilution buffer. Data were generated automatically by the Octet User Software. (B) tPA binding measurements with HMGB1 were analyzed. The results showed that the combined signals were the same as those of uncured sensor, indicating HMGB1 has no specific binding with tPA. (C) HBHP binding measurements with tPA were analyzed. The combined signals were the same as those of the uncured sensor, indicating HBHP also has no specific binding with tPA. (PDF 331 kb)
12974_2018_1267_MOESM2_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Journal of Neuroinflammation 1/2018 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Meistgelesene Bücher in der Neurologie & Psychiatrie

  • 2016 | Buch

    Neurologie

    Das Lehrbuch vermittelt Ihnen das gesamte Neurologie-Prüfungswissen für Ihr Medizinstudium und bereitet auch junge Assistenzärzte durch detailliertes Fachwissen optimal auf die Praxis vor. Die komplett überarbeitete Auflage enthält sechs neue, interdisziplinäre Kapitel.

    Herausgeber:
    Werner Hacke
  • 2016 | Buch

    Komplikationen in der Neurologie

    Das Buch schildert Ereignisse im Rahmen der Neuromedizin, die während der Diagnostik und Therapie neurologischer Erkrankungen und Symptome auftreten können. Die Fallbeispiele sensibilisieren Sie für mögliche Risikofaktoren, um das Auftreten solcher Komplikationen zu vermeiden.

    Herausgeber:
    Frank Block
  • 2017 | Buch

    Facharztwissen Psychiatrie, Psychosomatik und Psychotherapie

    Leitsymptome, Untersuchungsmethoden, Krankheitsbilder, Notfälle & Co. – mit der Neuauflage des "Facharztwissens" sind Sie auf die Facharztprüfung in Psychiatrie und Psychotherapie optimal vorbereitet. In dieser 2. Auflage sind die Kapitel zu psychosomatischen Störungen deutlich ausgebaut.

    Herausgeber:
    Prof. Dr. Dr. Frank Schneider
  • 2019 | Buch

    Kompendium der Psychotherapie

    Für Ärzte und Psychologen

    Dieses Werk wendet sich an Ärzte und Psychologen, die an psychiatrischen und psychosomatischen Kliniken oder an Psychotherapeutischen Ausbildungsinstituten arbeiten und in den vorhandenen Lehrbüchern der Psychotherapie den Brückenschlag zur …

    Herausgeber:
    Tilo Kircher